Gene Therapy For Rare Disease: Gene Therapy May Provide Hope for Treating Rare Diseases
 |
| Gene Therapy For Rare Disease |
What is Gene Therapy For Rare Disease?
Gene therapy is an experimental technique that uses genes to treat or prevent
disease. In gene therapy, a normal gene replaces a mutated gene or is inserted
into a cell to help treat a genetic disease. The normal gene delivers a missing
protein or overrides the expression of a mutated gene that is responsible for
disease. Despite much progress in basic research and clinical trials, gene
therapy for certain rare genetic diseases has shown promising results.
History of Gene Therapy For Rare Disease
The concept of Gene
Therapy For Rare Disease was first proposed in the early 1970s.
However, clinical gene therapy trial began in 1990 when a four-year-old girl
with adenosine deaminase (ADA) deficiency received gene therapy. She showed
improvement and has been well maintained on enzyme replacement therapy for the
past 31 years. Many other gene therapy clinical trials started in 1990s for
different diseases like cystic fibrosis, hemophilia, cancer etc. However, early
clinical trials produced mixed results due to technological limitations and safety
issues. But since 2000, gene therapy research has advanced significantly due to
improved gene delivery systems and vectors. Numerous clinical trials now show
promise in treating some rare genetic diseases.
Gene Therapy for Rare Monogenic Diseases
Many rare diseases are caused by a single mutated gene known as monogenic
disorders. Some examples include ADA deficiency, SCID, Duchenne muscular
dystrophy, hemophilia etc. Since these diseases have known genetic causes, they
represent optimal candidates for gene therapy. In gene therapy, a normal
functional gene is inserted into patient's cells and tissues using viral
vectors as delivery vehicles. This allows the added gene to produce the missing
or nonfunctional protein, thus treating the disorder. For example, gene therapy
has shown promising results for ADA deficiency by supplying the missing ADA
enzyme and curing the condition. Other monogenic diseases are also potential
targets of gene therapy.
Progress in Hemophilia Gene Therapy
Hemophilia is a genetic bleeding disorder caused by mutations in genes
responsible for blood clotting factor VIII (hemophilia A) or factor IX
(hemophilia B). Regular infusions of clotting factors can control bleeding but
are very expensive and lifelong. Gene therapy offers a potential one-time cure
by inserting the missing clotting factor gene directly into patient's liver
cells using viral vectors. This allows the liver to produce and secrete
adequate amounts of the clotting factor into bloodstream on an ongoing basis.
Hemophilia B gene therapy trials yielded positive results with most patients
maintaining protective factor levels for several years after a single
treatment. Hemophilia A gene therapy is also making progress with recent trials
showing potential benefits. If proven safe and effective in larger trials, gene
therapy could revolutionize treatment for hemophilia.
Challenges and Safety Concerns
While gene therapy trials provide hope for treating rare genetic diseases,
challenges remain in fully realizing its potential. Development of safe and
efficient gene delivery systems is crucial. Viral vectors used currently to
transport therapeutic genes into target cells have safety issues like unwanted
immune reactions, insertional mutagenesis etc. Non-viral delivery methods still
lack adequate efficiency compared to viruses. Other challenges include
optimizing therapeutic gene expression at desired target sites, immune
responses against viral vectors or gene-modified cells, inability to transduce
all relevant cells/tissues due to disease complexity.
Safety is the top priority in gene therapy research. Early gene therapy trials
met safety setbacks due to adverse events like development of leukemia in some
patients treated for X-linked SCID. This was linked to insertional mutagenesis
from viral vectors disrupting genes near integration sites. While no such
events have been reported in recent years, long-term effects of gene therapy
remain unknown. Careful pre-clinical testing and close patient monitoring in
clinical trials is required. Development of 'safer' vectors able to deliver
therapeutic genes with minimal genomic disruption is an active area of
research. Regulatory agencies also closely scrutinize safety aspects before
approving gene therapy trials. With progress in addressing challenges, safe and
effective gene therapy options may hopefully emerge for rare genetic diseases
in near future.
Gene therapy holds tremendous potential for treating currently incurable rare
genetic diseases. Despite historical setbacks, research over the last two
decades has demonstrated its promise through positive results in some clinical
trials. Ongoing advancements in vector engineering, delivery mechanisms and
manufacturing technologies are helping overcome limitations. Continued progress
supported by global collaboration will be key to fully realize the benefits of
gene therapy for patients affected by rare genetic conditions with no other
treatment options. With dedicated efforts, full or partial genetic correction
of certain diseases through gene therapy may someday transition from hope to
reality for many rare disease communities.
Get more insights on – Gene Therapy For Rare Disease
About Author:
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
Comments
Post a Comment